Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Lags Revenue Estimates

Company Performance - Arcus Biosciences reported a quarterly loss of $1.14 per share, which was worse than the Zacks Consensus Estimate of a loss of $1.02, and compared to a loss of $0.05 per share a year ago, indicating a significant decline in performance [1] - The company posted revenues of $28 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 14.24%, and a sharp decline from year-ago revenues of $145 million [2] - Over the last four quarters, Arcus Biosciences has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - Arcus Biosciences shares have lost about 40% since the beginning of the year, significantly underperforming the S&P 500, which declined by only 3.9% [3] - The current consensus EPS estimate for the coming quarter is -$1.08 on revenues of $30.7 million, and for the current fiscal year, it is -$4.13 on revenues of $123.83 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Arcus Biosciences belongs, is currently ranked in the top 31% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact the stock's performance [5]